EGFR and lung adenocarcinoma: Mechanistically, IL-1β acts on alveolar type 2 (AT2) cells, a cell-type of origin for lung adenocarcinoma, to enhance their progenitor stem cell capacity that is further exacerbated in the presence of an oncogenic EGFR mutation (9,10) (Fig. 4).